Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein in the urine: A warning sign for cognitive decline

22.11.2010
1. Small Amounts of Urinary Protein Predict More Rapid Cognitive Decline in Elderly Women Screening Efforts in Older Individuals May Be Warranted

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women. The study involved more than 1,200 women aged >70 years in the Nurses' Health Study who were phoned every two years for three cycles and tested for general cognition, verbal/word memory, verbal fluency (speed in making word associations), and working/short-term memory.

Julie Lin, MD (Brigham and Women's Hospital) and her colleagues found that participants with a urinary albumin-to-creatinine ratio of >5 mcg/mg at the start of the study experienced cognitive decline at a rate 2 to 7 times faster in all cognitive measures than that attributed to aging alone over an average 6 years of follow-up. "The strongest association was seen with a decline in the verbal fluency score, which has been attributed to progressive small vessel disease in the brain, which supports the view that albuminuria is an early marker of diffuse vascular disease," said Dr. Lin. "Therefore, in light of the aging U.S. population, which is at risk for cognitive decline and vascular disease, simple, non-invasive screening for albumin in the urine as an independent predictor for subsequent cognitive decline may represent an important public health issue."

Study co-authors include Fran Grodstein, PhD, Jae Hee Kang, PhD, and Gary Curhan, MD, ScD, (Brigham and Women's Hospital).

Disclosures: Dr. Curhan is a consultant for Takeda Pharmaceuticals; receives grants/research support from Astellas and honoraria from Takeda Pharmaceuticals. Dr. Lin, Dr. Grodstein, and Dr. Hee Kang reported no other financial disclosures.

The study abstract, "A Prospective Study of Albuminuria and Cognitive Decline in Women," [SA-FC355] will be presented as an oral presentation on Saturday, November 20 Day, Date at 5:18 PM MT in Room 405 of the Colorado Convention Center in Denver, CO.

2. Urinary Protein Excretion Increases Risk of Cognitive Impairment Simple Urine Tests Could Identify Individuals at Risk

Two characteristics of kidney disease¡ªexcreting protein in the urine (albuminuria) and low kidney function¡ªincrease individuals' risk of becoming confused and forgetful. To see whether these two characteristics are related or independent in their effects on cognitive decline, Manjula Kurella Tamura, MD (Stanford University) and her colleagues studied clinical data from 19,399 individuals participating in the Renal Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. A total of 1,184 participants (6.1%) developed cognitive impairment over an average follow-up of 3.8 years. Individuals with albuminuria were 1.31-1.57 times more likely to develop cognitive impairment compared to individuals without albuminuria. This association was strongest for individuals with normal kidney function (eGFR ¡Ý60 ml/min/1.73m2) and attenuated among individuals with low levels of kidney function. Conversely, low kidney function (eGFR

Study co-authors include Virginia Wadley, PhD, Mary Cushman, Frederick Unverzagt, PhD, Neil Zakai, MD, Brett Kissela, MD, David Warnock, MD, and William McClellan, MD (for the REGARDS Study Group, University of Alabama at Birmingham).

Disclosures: The study received pharmaceutical company support in addition to funding from the National Institute of Neurological Disorders and Stroke. Dr. Cushman is a consultant for Glaxo Smith Kline and receives grants/research support from Amgen. Dr. Unverzagt holds ownership in Eli Lilly. Dr. Warnock is a consultant for Genzyme and Gilhead, holds ownership in Parion and Relypsa, and receives honoraria from Genzyme, Amicus, Amgen, Gilhead, and Shire. Dr. McClellan receives grant/research support from and is a scientific advisor for Amgen. Dr. Wadley, Dr. Zakai, and Dr. Kissela reported no financial disclosures.

The study abstract, "Albuminuria, Kidney Function and the Incidence of Cognitive Impairment in US Adults," [SA-FC359] will be presented as an oral presentation on Saturday, November 20 Day, Date at 6:06 PM MT in Room 405 of the Colorado Convention Center in Denver, CO.

ASN Renal Week 2010, the largest nephrology meeting of its kind, will provide a forum for 13,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Renal Week 2010 will take place November 16 ¨C November 21 at the Colorado Convention Center in Denver, CO.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, the American Society of Nephrology (ASN) is the world's largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.

Shari Leventhal | EurekAlert!
Further information:
http://www.asn-online.org

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Morbid Obesity: Gastric Bypass and Sleeve Gastrectomy Are Comparable

17.01.2018 | Health and Medicine

Researchers identify new way to unmask melanoma cells to the immune system

17.01.2018 | Health and Medicine

Genetic discovery may help better identify children at risk for type 1 diabetes

17.01.2018 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>